One of the top tradeoffs faced by clinical stage biotech and pharmaceutical firms in raising capital to fund their clinical trial programs is the question of when and how to build a commercialization strategy, including navigating the complex work of securing market access. Precision’s Ross Maclean and co-author Liz Turner discuss three high-value tactics that should be conducted early to avoid costly missteps that could impact product success.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
